Agency
Desoto Hospital Association
Desoto Hospital Association was paid $8.29M by Medicaid between Jan 2018 and Dec 2024, across 108 billing codes. Its largest line is 41899, Unlisted procedure, dentoalveolar structures — 29% of everything it billed.
33Billing provider infoDESOTO HOSPITAL ASSOCIATION
MANSFIELD, LA 71052
MANSFIELD, LA 71052
33aNPI1467455154assigned 05/27/2005
33bProvider typeCommunity/Behavioral Health Agency
28Total paid$8.29M
24GClaims206,477
24DCodes billed108
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Community/Behavioral Health Agency providers in Louisiana
Rank by total paid#29 of 374
Median peer was paid$831K
This provider vs. median10.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 19,181 | $561K | |
| 2019 | 20,264 | $576K | |
| 2020 | 17,530 | $363K | |
| 2021 | 35,969 | $1.35M | |
| 2022 | 36,218 | $1.78M | |
| 2023 | 39,099 | $2.19M | |
| 2024incomplete | 38,216 | $1.47M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 41899 | Unlisted procedure, dentoalveolar structures | 29% | 4,464 | 3,760 | $2.42M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 23% | 12,202 | 10,599 | $1.87M |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 14% | 3,748 | 3,274 | $1.15M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.5% | 3,732 | 3,255 | $370K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.9% | 960 | 790 | $322K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 3.1% | 7,715 | 6,818 | $253K |
| G0330 | Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room | 2.8% | 412 | 365 | $230K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 2.6% | 1,007 | 864 | $212K |
| 80053 | Comprehensive metabolic panel | 2.0% | 22,606 | 19,216 | $162K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.7% | 4,037 | 2,816 | $138K |
| 71046 | Radiologic examination, chest; 2 views | 1.4% | 3,018 | 2,606 | $115K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.2% | 8,704 | 7,659 | $99K |
96 more codes
| 36415 | Collection of venous blood by venipuncture | 1.1% | 41,388 | $95K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.1% | 4,543 | $94K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.1% | 1,721 | $93K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.1% | 1,937 | $91K |
| 80061 | Lipid panel | 1.1% | 9,441 | $88K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 8,095 | $54K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 11,832 | $48K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,246 | $46K |
| 84439 | <1% | 6,935 | $44K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 252 | $22K |
| 93000 | <1% | 391 | $19K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 512 | $18K |
| G0378 | Hospital observation service, per hour | <1% | 273 | $18K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 45 | $18K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 57 | $16K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 569 | $16K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,324 | $16K |
| 0001A | <1% | 461 | $14K | |
| 0002A | <1% | 385 | $13K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 846 | $10K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,039 | $10K |
| 74019 | <1% | 80 | $7K | |
| 81001 | <1% | 3,055 | $6K | |
| 87631 | <1% | 1,976 | $4K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 48 | $4K |
| 84481 | <1% | 451 | $4K | |
| 80306 | <1% | 627 | $4K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 686 | $4K |
| 87390 | <1% | 183 | $4K | |
| 96376 | <1% | 124 | $3K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 144 | $3K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 23 | $3K |
| 97162 | <1% | 67 | $3K | |
| 82728 | <1% | 215 | $3K | |
| 83735 | <1% | 645 | $3K | |
| 84153 | <1% | 190 | $2K | |
| 72100 | <1% | 62 | $2K | |
| 86702 | <1% | 183 | $2K | |
| 83655 | <1% | 150 | $2K | |
| 86696 | <1% | 118 | $2K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 48 | $2K |
| 73630 | <1% | 34 | $2K | |
| 86780 | <1% | 146 | $1K | |
| 71045 | Radiologic examination, chest; single view | <1% | 61 | $1K |
| 87486 | <1% | 60 | $1K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 17 | $1K |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 1,077 | $1K |
| 86701 | <1% | 183 | $1K | |
| 82043 | <1% | 445 | $1K | |
| 86695 | <1% | 117 | $1K | |
| 82570 | <1% | 483 | $1K | |
| 0011A | <1% | 71 | $1K | |
| 97010 | <1% | 1,116 | $1K | |
| 0003A | <1% | 25 | $1K | |
| 84484 | <1% | 125 | $922.47 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,092 | $901.11 |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 393 | $888.67 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 91 | $796.50 |
| 82607 | <1% | 66 | $794.72 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 289 | $761.51 |
| 80069 | <1% | 199 | $749.11 | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 13 | $735.79 |
| 82746 | <1% | 63 | $730.59 | |
| J3490 | Unclassified drugs | <1% | 1,690 | $718.80 |
| 0012A | <1% | 38 | $630.36 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 14 | $616.70 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,429 | $556.91 |
| 83550 | <1% | 47 | $422.64 | |
| 83540 | <1% | 63 | $419.50 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 71 | $379.61 |
| 81003 | <1% | 301 | $371.35 | |
| 87807 | <1% | 25 | $351.82 | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 5,478 | $337.45 |
| 83880 | <1% | 17 | $235.57 | |
| 82550 | <1% | 34 | $171.63 | |
| 82553 | <1% | 17 | $162.03 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,861 | $161.58 |
| 82565 | <1% | 47 | $153.60 | |
| 80051 | <1% | 32 | $140.20 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 786 | $135.46 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 470 | $116.55 |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 5,030 | $107.85 |
| 81025 | <1% | 13 | $96.16 | |
| 82947 | <1% | 41 | $82.53 | |
| 91307 | <1% | 15 | $61.78 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 368 | $56.51 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 178 | $46.55 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 12 | $19.36 |
| 84156 | <1% | 16 | $12.12 | |
| 91300 | <1% | 929 | $0.75 | |
| 97014 | <1% | 274 | $0.48 | |
| 91301 | <1% | 80 | $0.02 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 801 | $0.00 |
| 90832 | Psychotherapy session, about 30 minutes | 0% | 31 | $0.00 |
| 91305 | 0% | 60 | $0.00 | |
| G2061 | Qualified nonphysician healthcare professional online assessment and management service, for an established patient, for up to seven days, cumulative time during the 7 days; 5-10 minutes | 0% | 71 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialEPPLER, TODD (CEO)